查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
扩张型心肌病治疗的全球市场-2022-2029
市场调查报告书
商品编码
1140663

扩张型心肌病治疗的全球市场-2022-2029

Global Dilated Cardiomyopathy Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

扩张型心肌病治疗市场规模预计将在 2021 年达到 4.049 亿美元，在预测期间（2022-2029 年）以 5.90% 的复合年增长率增长。

扩张型心肌病 (DCM) 是一种心肌疾病，通常始于心臟的主泵室（左心室）。心室变弱，扩大，无法泵血。心力衰竭的一个常见原因是心臟无法为身体提供足够的血液，但扩张型心肌病也会导致心律失常、血栓或猝死。扩张型心肌病影响所有年龄段的人，包括婴儿和儿童，但最常见于 20 至 50 岁的男性。

市场动态

全球扩张型心肌病治疗市场的增长受到某些因素的推动，例如心脏病患病率上升、心肌感染人数增加以及药物和酒精滥用。

在预测期内，心脏病患病率的上升预计将推动全球扩张型心肌病治疗市场。

扩张型心肌病每年占所有充血性心力衰竭病例的 30-40%。扩张型心肌病的估计患病率为 1:2500。这种疾病是心力衰竭最常见的原因之一。尸检发现的扩张型心肌病的发病率估计为每年每 100,000 人 4.5 例，而临床发病率为每年每 100,000 人 2.45 例。充血性心脏病的日益流行增加了对有效药物和治疗的紧迫性，从而使扩张型心肌病治疗市场受益。

根据世界卫生组织 (WHO) 的 2020 年统计数据，缺血性心脏病占全球所有死亡人数的 16%。根据 2020 年 2 月在法国发表的题为心力衰竭 (HF) 的文章。根据慢性心力衰竭治疗管理和现实生活中心臟失代偿的风险，法国约有 100 万人患有心衰。儘管有完善的治疗管理，但仍有大约 70,000 例死亡和超过 150,000 例住院与 HF 相关。

随着对扩张型心肌病治疗的需求不断增长，几家大公司已启动临床试验，以开发治疗扩张型心肌病的药物。扩张型心肌病被视为充血性心力衰竭，因为没有特定的 FDA 批准药物。

新开发的用于治疗扩张型心肌病的药物包括以下药物。

ARRY-371797（也称为 ARRY-797）是 Array 科学家发现的一种口服 p38 丝裂原活化蛋白激□ (MAPK) 抑製剂。一项针对因 Lamin A/C 基因突变导致的扩张型心肌病患者的治疗正在进行中的 3 期研究。 2019 年，辉瑞收购了 Array Biopharma 以扩大其管道。它以 PF-07265803 的名称包含在辉瑞（Pfizer）公司的第 3 阶段管道中，用于治疗扩张型心肌病患者。

2020 年 2 月，庆应义塾大学的一个研究小组批准了将 iPS 细胞衍生的心肌细胞移植给患有严重心力衰竭的患者。目标是在 2020 年内进行研究，目标是扩张型心肌病患者，其中心肌细胞的收缩功能降低。

扩张型心肌病药物的副作用抑制市场增长

然而，扩张型心肌病药物对患者造成严重不适的副作用限制了市场。此外，可植入设备的可用性和有前途的基因治疗是市场的障碍。

行业分析

全球扩张型心肌病治疗市场根据波特五力分析、管道分析、监管分析、流行病学和未满足的需求等各种行业因素对市场进行了深入分析。

细分分析

在预测期间（2022-2029 年），药物类别部分预计将以最快的复合年增长率增长。

扩张型心肌病治疗市场根据药物类别分为血管紧张素转换□ (ACE) 抑製剂、β 受体阻滞剂、醛固酮拮抗剂、血管紧张素 II 受体阻滞剂等。由于扩张型心肌病治疗对重磅炸弹的需求不断增加，特别是在发达地区，血管紧张素 II 受体阻滞剂预计将占据最大的市场份额。

另一方面，醛固酮拮抗剂已被证实与 ARB 或 ACE 抑製剂联合使用可有效抑制杜氏肌营养不良症 (DMD) 的进展，预计在预测期内将以最高的复合年增长率增长。.这一适应症的批准将进一步加速整体醛固酮拮抗剂的销售，并对市场增长产生积极影响。一些研究表明，血管紧张素受体阻滞剂如缬沙坦可将住院机会降低 28%。这些药物还通过降低 37% 的死亡率和减少住院频率来使收缩性心脏病患者受益。常见的抗心律失常药物包括胺碘酮、普鲁卡因胺和利多卡因。 Corlanor 是一种超极化激活的环核甘酸门控通道阻滞剂，可降低心臟窦房结的自发起搏器活动。美国 FDA 批准 Corlanor（依布雷定）用于治疗 6 个月至 18 岁儿童扩张型心肌病引起的稳定症状性心力衰竭（HF）是窦性心律的症状性 DCM，NYHA/Ross 分级对 116 名 6 个月至 <18 岁患有 II 至 IV HF 和 □45% 左心室射血力的患者进行的双盲、安慰剂对照试验。主要终点是在第一个滴定期后静息心率较基线降低□20%，而无心动过缓或症状。

区域分析

北美在全球扩张型心肌病药物市场中占有最大的市场份额。

心血管疾病发病率上升、完善的保险政策以及使用先进的医疗保健基础设施是主要驱动力。在美国，2020 年心衰的总医疗成本（直接和间接）估计为 436 亿美元，其中超过 70% 归因于医疗成本。美国在该地区拥有最大的市场份额。这是由于该国老年人口的增长和心脏病的增加，这推动了该地区的需求。因此，随着心血管疾病的增加，扩张型心肌病的市场也会增加。

此外，市场参与者正在投资研发以实施新的扩张型心肌病治疗药物。例如，2019 年 7 月，利用人工智能发现药物的 Recursion Pharmaceuticals 在由 Baillie Gifford 领投的一轮融资中筹集了 1.21 亿美元。该公司是一家于 2018 年筹集资金的新药发现初创公司，该领域的投资者希望通过计算机视觉和机器学习等技术改变成本高昂且费力的药物发现过程。 Recursion 自己生产罕见病药物，并寻求与武田、赛诺菲等大型製药公司合作治疗其他罕见病，并希望在肿瘤学和炎症等领域与製药公司达成交易。我在这里。

竞争格局

全球扩张型心肌病治疗市场由多家主要参与者主导，如 Zensun Shanghai Sci &Tech Co Ltd、Capricor Therapeutics, Inc、AstraZeneca plc、Vericel Corporation、Pfizer Inc、t2cure GmbH、MyoKardia、Kasiak Research Pvt。来自竞争领先公司正在采取多种增长战略，包括产品发布、收购和合作伙伴关係，为全球扩张型心肌病治疗市场的增长做出贡献。例如，2019 年 10 月，诺华公司在美国食品药品监督管理局 (FDA) 批准了 Entresto (sacubitril/valsartan)，用于治疗患有全身性左心室收缩功能障碍 (HF) 的症状性心力衰竭 (HF) 1 年的儿科患者。年龄及以上。（FDA）批准。 Entresto 有望降低 NT-proBNP 并改善心血管预后。

值得关注的重点公司

辉瑞公司

概述辉瑞公司是一家美国跨国製药公司，在癌症、炎症、心血管和其他治疗领域提供药物、疫苗、医疗设备和消费者保健产品。辉瑞日本公司在 15 个治疗领域拥有 150 多种产品组合。该公司为广泛的医学领域开发和製造药物和疫苗，包括免疫学、肿瘤学、心脏病学、内分泌学和神经学。

产品组合 Camdios 是第一个可用于心肌病患者的新型治疗选择。

重大进展。 2022 年 8 月，辉瑞停止了扩张型心肌病治疗药物 Emprumapimod 的开发。

全球扩张型心肌病治疗市场报告提供了大约 40 多个市场数据表、45 多个图表和 180 页的结构。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物类别划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 心脏病增加
    • 吸毒和酗酒增加
  • 限制因素
    • 扩张型心肌病药物的副作用
  • 商机
  • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 监管分析
  • 未满足的需求

第 6 章按药物类别

  • 血管紧张素转换□ (ACE) 抑製剂
  • β-受体阻滞剂
  • 醛固酮拮抗剂
  • 血管紧张素 II 受体阻滞剂
  • 其他

第 7 章按销售渠道

  • 医院和诊所
  • 在线频道
  • 其他

第 8 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 9 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 10 章公司简介

  • 阿斯利康公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Zensun Shanghai Sci & Tech Co Ltd
  • Pfizer Inc.
  • Capricor Therapeutics, Inc.
  • MyoKardia
  • Kasiak Research Pvt. Ltd.
  • Array BioPharma
  • Vericel Corporation
  • t2cure GmbH（*List is not exhaustive）

第11章 DataM

简介目录
Product Code: DMPH2586

Market Overview

Dilated Cardiomyopathy Therapeutics Market size was valued at US$ 404.9 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.90% during the forecast period (2022-2029).

Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.

Market Dynamics

The global dilated cardiomyopathy therapeutics market growth driven by certain factors such by rising prevalence of heart problems, the increasing number of people suffering from cardiac muscle infections, and drug or alcohol abuse.

Rising prevalence of heart problems, is expected to drive the global dilated cardiomyopathy therapeutics market during the forecast period

Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

According to statistics from the World Health Organization (WHO) for 2020, ischemic heart disease is to blame for 16% of all fatalities worldwide. According to a February 2020 article titled "Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting," approximately one million people in France would be affected by HF. Despite well-defined treatment management, there are nearly 70,000 HF-related deaths and more than 150,000 hospitalizations.

With the rising demand for dilated cardiomyopathy treatment, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy. There is no specific FDA-approved drug for dilated cardiomyopathy because of which the treatment administered is the same as that for congestive heart failure.

Some of the emerging drugs for the treatment of dilated cardiomyopathy are:

ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial to treat patients suffering from dilated cardiomyopathy because of a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for the treatment of patients affected by dilated cardiomyopathy.

In February 2020, a Keio University research team was given the green light to transplant heart muscle cells derived from iPS cells into patients who have experienced severe heart failure. The study aims to conduct study by the end of 2020 and targets patients with dilated cardiomyopathy, which lowers the systolic function of heart muscle cells.

Side effects associated with dilated cardiomyopathy therapeutics hampering the growth of the market

However, the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market. Moreover, the availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

Industry Analysis

The global dilated cardiomyopathy therapeutics market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, pipeline analysis, regulatory analysis, regulatory analysis, epidemiology, unmet needs etc.

Segment Analysis

The drug class segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the dilated cardiomyopathy therapeutics market is segmented by drug class into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers, and others. The angiotensin II receptor blockers drug class is estimated to account for the largest market share, owing to the rising demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions.

On the other hand, the aldosterone antagonists are expected to grow at the highest CAGR over the forecast period due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. According to some studies, the angiotensin receptor blockers such as valsartan can reduce the probability of hospitalization by 28%. These drugs are also effective for patients with systolic heart disease by reducing deaths by 37% and reducing hospitalization frequency. Common anti-arrhythmia medications include amiodarone, procainamide, and lidocaine. Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the cardiac sinus node's spontaneous pacemaker activity. The US FDA approval of Corlanor (ivabradine) for the treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years was based on a randomized, double-blind, placebo-controlled trial in 116 patients aged 6 months to less than 18 years with symptomatic DCM in sinus rhythm, NYHA/Ross class II to IV HF, and left ventricular ejection fraction ≤45%. The study's primary endpoint was ≥ a 20% reduction in resting heart rate from baseline without bradycardia or symptoms after an initial titration period.

Geographical Analysis

North America region holds the largest market share of the global dilated cardiomyopathy therapeutics market

The rising incidence of cardiovascular diseases, well-established insurance policies, and the availability of advanced healthcare infrastructure are the major factors. In the USA, the total cost of care (direct and indirect costs) for HF in 2020 is estimated at $43.6 billion, with over 70% of costs attributed to medical costs. In this region, the United States holds the largest market share due to rising geriatric populations, an increasing number of heart diseases in the country, which boosts the demand in this region. Hence, as the number of cardiovascular diseases increases, the market for dilated cardiomyopathy also increases.

Besides, the market players are investing in research and development to conduct new treatment drugs for dilated cardiomyopathy. For instance, in July 2019, Recursion Pharmaceuticals, which uses artificial intelligence to discover drugs, has raised $121 million in a round led by Baillie Gifford. The company is a new drug discovery start-up to raise funds in 2018, as investors flock to the sector hoping that the costly and cumbersome process of finding a drug will be transformed by techniques such as computer vision and machine learning. Recursion is trying to make its own drugs for rare diseases and partner with major pharmaceutical companies such as Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma companies in areas such as oncology and inflammation.

Competitive Landscape

The global dilated cardiomyopathy therapeutics market is moderately competitive with several major players, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer Inc., t2cure GmbH, MyoKardia, Kasiak Research Pvt. Ltd., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the dilated cardiomyopathy therapeutics market globally. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. Entresto reduces NT-proBNP and is expected to improve cardiovascular outcomes.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: Camzyos is the first novel therapy option available for cardiomyopathy patients.

Key Developments: In August, 18th 2022, Pfizer discontinued the development of dilated cardiomyopathy drug emprumapimod.

The global dilated cardiomyopathy therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug class
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising prevalence of heart diseases
    • 4.2.2. Increasing drugs and alcohol abuse
    • 4.2.3. XX
  • 4.3. Restraints:
    • 4.3.1. Side-effects of dilated cardiomyopathy drugs
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. By Drug class

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment.
  • 6.3. Market Attractiveness Index, By Drug Class Segment
    • 6.3.1. Angiotensin-converting enzyme (ACE) Inhibitors*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Beta-blockers
    • 6.3.3. Aldosterone antagonists
    • 6.3.4. Angiotensin II Receptor Blockers
    • 6.3.5. Others

7. By Distribution Channel

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 7.3. Market Attractiveness Index, By Distribution Channel Segment
    • 7.3.1. Hospitals & Clinics*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Online Channels
    • 7.3.3. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. The U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. The U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Italy
      • 8.3.5.5. Spain
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia Pacific
  • 8.6. The Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 10.1. AstraZeneca plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. Zensun Shanghai Sci & Tech Co Ltd
  • 10.3. Pfizer Inc.
  • 10.4. Capricor Therapeutics, Inc.
  • 10.5. MyoKardia
  • 10.6. Kasiak Research Pvt. Ltd.
  • 10.7. Array BioPharma
  • 10.8. Vericel Corporation
  • 10.9. t2cure GmbH (*List is not exhaustive)

11. DataM Intelligence

  • 11.1. Appendix
  • 11.2. About Us and Services
  • 11.3. Contact Us